BR0302017A - Composição farmacêutica a base de um agonista do receptor central de benzodiazepìnicos - Google Patents

Composição farmacêutica a base de um agonista do receptor central de benzodiazepìnicos

Info

Publication number
BR0302017A
BR0302017A BR0302017-7A BR0302017A BR0302017A BR 0302017 A BR0302017 A BR 0302017A BR 0302017 A BR0302017 A BR 0302017A BR 0302017 A BR0302017 A BR 0302017A
Authority
BR
Brazil
Prior art keywords
weight
pharmaceutical composition
receptor agonist
composition based
benzodiazepine receptor
Prior art date
Application number
BR0302017-7A
Other languages
English (en)
Other versions
BR0302017B1 (pt
Inventor
Carlos Oliani
Adriano P Coelho
Heny C Zaniboni
Guido Vandoni
Original Assignee
Sigma Pharma Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Pharma Ltda filed Critical Sigma Pharma Ltda
Priority to BRPI0302017-7A priority Critical patent/BR0302017B1/pt
Priority to US10/559,290 priority patent/US8168625B2/en
Priority to MXPA05013091A priority patent/MXPA05013091A/es
Priority to AT04734794T priority patent/ATE462436T1/de
Priority to RU2005136684/15A priority patent/RU2335288C2/ru
Priority to DE602004026299T priority patent/DE602004026299D1/de
Priority to PCT/BR2004/000076 priority patent/WO2004105767A1/en
Priority to EP04734794A priority patent/EP1633366B1/en
Priority to ES04734794T priority patent/ES2345984T3/es
Publication of BR0302017A publication Critical patent/BR0302017A/pt
Publication of BR0302017B1 publication Critical patent/BR0302017B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA A BASE DE UM AGONISTA DO RECEPTOR CENTRAL DE BENZODIAZEPìNICOS". A presente invenção descreve o uso de compostos farmacêuticos em composições farmacêuticas para administração sublingual incluindo, como princípio ativo dos mesmos, um agonista do receptor central dos benzodiazepínicos escolhido entre diazepam, lorazepam, bromazepam, triazolam, alprazolam, flunitrazepam, nitrazepam e maleato de midazolam em mistura com um excipiente farmacêutico composto por, pelo menos, 70% do peso da formulação final contendo 40 - 45% em peso de lactose, 15 - 27% em peso de sorbitol e 12 - 16% em peso de celulose.
BRPI0302017-7A 2003-06-02 2003-06-02 Composição farmacêutica sublingual a base de um agonista do receptor central de benzodiazepínicos BR0302017B1 (pt)

Priority Applications (9)

Application Number Priority Date Filing Date Title
BRPI0302017-7A BR0302017B1 (pt) 2003-06-02 2003-06-02 Composição farmacêutica sublingual a base de um agonista do receptor central de benzodiazepínicos
US10/559,290 US8168625B2 (en) 2003-06-02 2004-05-26 Pharmaceutical composition based on agonist of benzodiazepine
MXPA05013091A MXPA05013091A (es) 2003-06-02 2004-05-26 Composicion farmaceutica basada en agonistas de benzodiazepina.
AT04734794T ATE462436T1 (de) 2003-06-02 2004-05-26 Pharmazeutische zusammensetzung auf basis eines benzodiazepin-agonisten
RU2005136684/15A RU2335288C2 (ru) 2003-06-02 2004-05-26 Фармацевтическая композиция на основе агониста бензодиазепина
DE602004026299T DE602004026299D1 (de) 2003-06-02 2004-05-26 Pharmazeutische zusammensetzung auf basis eines benzodiazepin-agonisten
PCT/BR2004/000076 WO2004105767A1 (en) 2003-06-02 2004-05-26 Pharmaceutical composition based on agonist of benzodiazepine
EP04734794A EP1633366B1 (en) 2003-06-02 2004-05-26 Pharmaceutical composition based on agonist of benzodiazepine
ES04734794T ES2345984T3 (es) 2003-06-02 2004-05-26 Composicion farmaceutica basada en agonista de la benzodiacepina.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0302017-7A BR0302017B1 (pt) 2003-06-02 2003-06-02 Composição farmacêutica sublingual a base de um agonista do receptor central de benzodiazepínicos

Publications (2)

Publication Number Publication Date
BR0302017A true BR0302017A (pt) 2005-06-28
BR0302017B1 BR0302017B1 (pt) 2014-10-29

Family

ID=36596112

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0302017-7A BR0302017B1 (pt) 2003-06-02 2003-06-02 Composição farmacêutica sublingual a base de um agonista do receptor central de benzodiazepínicos

Country Status (9)

Country Link
US (1) US8168625B2 (pt)
EP (1) EP1633366B1 (pt)
AT (1) ATE462436T1 (pt)
BR (1) BR0302017B1 (pt)
DE (1) DE602004026299D1 (pt)
ES (1) ES2345984T3 (pt)
MX (1) MXPA05013091A (pt)
RU (1) RU2335288C2 (pt)
WO (1) WO2004105767A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US9289583B2 (en) * 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8252328B2 (en) * 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US9066847B2 (en) 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8252329B2 (en) * 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US20070260491A1 (en) * 2006-05-08 2007-11-08 Pamela Palmer System for delivery and monitoring of administration of controlled substances
DE102006027792A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Antidepressiva-Kombinations-Wafer
US20070299687A1 (en) * 2006-06-23 2007-12-27 Pamela Palmer Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed
WO2009021106A1 (en) * 2007-08-07 2009-02-12 Acelrx Pharmaceuticals, Inc. Compositions and methods for procedural sedation and analgesia using oral transmucosal dosage forms
ES2403193T3 (es) * 2008-02-05 2013-05-16 Laboratorios Bago S.A. Composiciones que comprenden alprazolam para el tratamiento del insomnio primario y del insomnio asociado con estados de ansiedad y procedimientos para su preparación
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
AU2014205356A1 (en) * 2013-01-09 2015-07-30 Edgemont Pharmaceuticals Llc Controlled release formulations of lorazepam
BR112017013311B1 (pt) 2014-12-23 2022-05-31 Acelrx Pharmaceuticals, Inc Aparelho para a dispensação de formas de dosagem via oral e transmucosal
CN122182527A (zh) 2016-05-05 2026-06-12 阿奎斯蒂弗医疗股份有限公司 增强递送的肾上腺素组合物
JP7431724B2 (ja) * 2017-09-27 2024-02-15 アクエスティブ セラピューティクス インコーポレイテッド 増強された透過を有する医薬組成物
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US10898493B2 (en) 2019-04-12 2021-01-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease
WO2023076281A1 (en) 2021-10-25 2023-05-04 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229447A (en) * 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
GB8613689D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
US20040253307A1 (en) * 2003-02-04 2004-12-16 Brian Hague Sugar-free oral transmucosal solid dosage forms and uses thereof

Also Published As

Publication number Publication date
RU2335288C2 (ru) 2008-10-10
DE602004026299D1 (de) 2010-05-12
WO2004105767A1 (en) 2004-12-09
BR0302017B1 (pt) 2014-10-29
EP1633366B1 (en) 2010-03-31
EP1633366A4 (en) 2008-02-27
US8168625B2 (en) 2012-05-01
US20060134200A1 (en) 2006-06-22
RU2005136684A (ru) 2007-07-20
ATE462436T1 (de) 2010-04-15
ES2345984T3 (es) 2010-10-07
MXPA05013091A (es) 2006-03-09
EP1633366A1 (en) 2006-03-15

Similar Documents

Publication Publication Date Title
MXPA05013091A (es) Composicion farmaceutica basada en agonistas de benzodiazepina.
NO20032905D0 (no) Nye benzodiazepiner og beslektede heterocykliske derivater som er anvendelige som orexinreseptorantagonister
NO20034230D0 (no) 1,2,3,4-tetrahydroisokinolin-derivater som urotensin II reseptor-antagonister
DE60335891D1 (de) Sulphonylaminoessigsaeure derivate und deren verwendung als orexin rezeptor antagoniste
NO20024339D0 (no) 1,2,3,4-Tetrahydroisokinolin-derivater
WO2001085257A3 (en) Opioid antagonist compositions and dosage forms
MY129150A (en) Novel sulfamides
UY28026A1 (es) 4-piperazinilbencenosulfonilindoles y usos de los mismos.
NO20042844L (no) 4-(piperidyl- og pyrrolidyl-alkyl-ureido)-kinoliner som uprotensin II reseptor-antagonister
NO323467B1 (no) Farmasoytisk sammensetning som omfatter antihypertensivt middel og en VEGF-reseptortyrosinkinaseinhibitor, et testsett som omfatter middelet og inhibitorene og anvendelse av dem for fremstilling av et medikament
DE602004021786D1 (de) Tetrahydroisochinolylacetamidderivate zur verwendung als orexinrezeptorantagonisten
ES2151672T3 (es) Composiciones de rapida disolucion oral para agonistas de dopamina.
ES2154167A1 (es) Aminoderivados ciclicos antagonistas del receptor ccr-3.
SV2002000205A (es) Compuestos farmaceuticos ref. x-01095
DE69532162D1 (de) Cannabinoid-rezeptor-antagonisten
WO2005032464A3 (en) Phenyl pyrrolidine ether tachykinin receptor antagonists
HUP0203836A3 (en) 1,3-disubstituted pyrrololidines as alpha-2-adrenoceptor antagonists, process for their preparation and pharmaceutical compositions containing them and their use
HUP0301346A3 (en) New combination of serotonin agonist (5ht2) and antagonist (5ht6) as pharmaceutical composition and process for its preparation
DE60203797D1 (de) Benzo[d]azepin-derivative als 5-ht6-rezeptor-antagonisten
MY144897A (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
BR9909486A (pt) Compostos calcilìticos
MXPA04001252A (es) Nuevos heterociclos benzo-fusionados como antagonistas de endotelina.
MY140724A (en) Novel arylethene-sulfonamides
HUP0303513A3 (en) Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonists and antagonists, their use and pharmaceutical compositions containing them
UA86371C2 (ru) Фармацевтическая композиция на основе агониста бензодиазепина

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: BASEADO NO ART. 216 1 DA LPI, APRESENTE COPIA AUTENTICADA DA PROCURACAO PARA QUE ESTA SEJA ACEITA.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: EMS SIGMA PHARMA LTDA (BR/SP)

B25G Requested change of headquarter approved

Owner name: EMS SIGMA PHARMA LTDA (BR/SP)

Free format text: SEDE ALTERADA CONFORME PETICAO NO 20130095866, DE 27/12/2013.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/10/2014, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2517 DE 02-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.